The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review
Open accessAbstract
Objective: To assess the effects of oral mucolytics in adults with stable chronic bronchitis and chronic obstructive pulmonary disease. Design: Systematic review of randomised controlled trials that compared at least two months of regular oral mucolytic drugs with placebo. Studies: Twenty three randomised controlled trials in outpatients in Europe and United States. Main outcome measures: Exacerbations, days of illness, lung function, adverse events. Results: Compared with placebo, the number of exacerbations was significantly reduced in subjects taking oral mucolytics (weighted mean difference −0.07 per month, 95% confidence interval −0.08 to −0.05, P<0.0001). Based on the annualised rate of exacerbations in the control subjects of 2.7 a year, this is a 29% reduction. The number needed to treat for one subject to have no exacerbation in the study period would be 6. Days of illness also fell (weighted mean difference −0.56, −0.77 to −0.35, P<0.0001). The number of subjects who had no exacerbations in the study period was greater in the mucolytic group (odds ratio 2.22, 95% confidence interval 1.93 to 2.54, P<0.0001). There was no difference in lung function or in adverse events reported between treatments. Conclusions: In chronic bronchitis and chronic obstructive pulmonary disease, treatment with mucolytics is associated with a reduction in acute exacerbations and days of illness. As these drugs have to be taken long term, they could be most useful in patients who have repeated, prolonged, or severe exacerbations of chronic obstructive pulmonary disease. What is already known on this topic: Mucolytic drugs have properties that may be beneficial in chronic obstructive pulmonary disease These drugs are not prescribed in the United Kingdom and Australasia, although they are widely used in many other countries Drugs that reduce exacerbations may reduce the morbidity and healthcare costs associated with progressively severe disease What this study adds: Regular use of mucolytic drugs for at least two months significantly reduces exacerbations and days of illness compared with placebo in patients with chronic bronchitis and chronic obstructive pulmonary disease Exacerbations that do occur may not be as severe, and the benefit may be greater in those with more severe disease Reductions are modest and treatment may not be cost effective
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chronic Obstructive Pulmonary Disease
(2018) · Questions for the Final FFICM Structured Oral Examination · doi:10.1017/9781108233712.025 · Cited by 2,689
(1958) · Journal of the American Pharmaceutical Association (Scientific ed.) · doi:10.1002/jps.3030470133 · Cited by 2,489
Effect of Exacerbation on Quality of Life in Patients with Chronic Obstructive Pulmonary Disease
SEEMUNGAL, T. A. R., DONALDSON, G. C., PAUL, E. A., BESTALL, J. C., JEFFRIES, D. J., & WEDZICHA, J. A. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.5.9709032 · Cited by 2,312
Moher, D., Jadad, A. R., Nichol, G., Penman, M., Tugwell, P., & Walsh, S. (1995) · Controlled Clinical Trials · doi:10.1016/0197-2456(94)00031-w · Cited by 1,308
Review papers : The statistical basis of meta-analysis
Fleiss, J. (1993) · Statistical Methods in Medical Research · doi:10.1177/096228029300200202 · Cited by 1,281
Griffiths, T., Burr, M., Campbell, I., Lewis-Jenkins, V, Mullins, J., Shiels, K., Turner-Lawlor, P., Payne, N., Newcombe, R., Lonescu, A., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(99)07042-7 · Cited by 952
Assessing the Quality of Randomized Controlled Trials:Current Issues and Future Directions
Moher, D., Jadad, A. R., & Tugwell, P. (1996) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462300009570 · Cited by 436
Enslein, K. (1978) · Technometrics · doi:10.1080/00401706.1978.10489655 · Cited by 362
Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease
Poole, P., Black, P. N., & Cates, C. J. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001287.pub4 · Cited by 225
Self-citationCOLLET, J. P., SHAPIRO, S., ERNST, P., RENZI, P., DUCRUET, T., ROBINSON, A., & the PARI-IS Study Steering Committee and Research Group (1997) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.156.6.9612096 · Cited by 221
Boman, G., Bäcker, U., Larsson, S., Melander, B., & Wåhlander, L. (1983) · PubMed · Cited by 214
Trends in COPD Morbidity and Mortality in the United States
Feinleib, M., Rosenberg, H. M., Collins, J. G., Delozier, J. E., Pokras, R., & Chevarley, F. M. (1989) · American Review of Respiratory Disease · doi:10.1164/ajrccm/140.3_pt_2.s9 · Cited by 189
Petty, T. L. (1990) · Chest · doi:10.1378/chest.97.1.75 · Cited by 160
Rahman, I., Skwarska, E., & MacNee, W. (1997) · Thorax · doi:10.1136/thx.52.6.565 · Cited by 142
Rasmussen, J., & Glennow, C. (1988) · European Respiratory Journal · doi:10.1183/09031936.93.01040351 · Cited by 114
Hansen, N. C. G., Skriver, A., Brorson-Riis, L., Balsløv, S., Evald, T., Maltbæk, N., Gunnersen, G., Garsdal, P., Sander, P., Pedersen, J., et al. (1994) · Respiratory Medicine · doi:10.1016/s0954-6111(05)80337-3 · Cited by 104
Allegra, L., Cordaro, C. I., & Grassi, C. (2009) · Respiration · doi:10.1159/000196540 · Cited by 72
S-Carboxymethylcysteine in the Fluidification of Sputum and Treatment of Chronic Airway Obstruction
Edwards, G. F., Steel, A. E., Scott, J. K., & Jordan, J. W. (1976) · CHEST Journal · doi:10.1378/chest.70.4.506 · Cited by 72
Oral fabrol (oral N-acetylcysteine) in chronic bronchitis
Parr, G., & Huitson, A. (1987) · British Journal of Diseases of the Chest · doi:10.1016/0007-0971(87)90182-3 · Cited by 65
Jackson, I. M., Barnes, J., & Cooksey, P. (1984) · Journal of International Medical Research · doi:10.1177/030006058401200312 · Cited by 63
Rubin, B. K., Ramirez, O., & Ohar, J. A. (1996) · CHEST Journal · doi:10.1378/chest.109.2.348 · Cited by 57
Ekberg‐Jansson, A., Larson, M., MacNee, W., Tunek, A., Wahlgren, L., Wouters, E. F. �., Larsson, S., & for the N-isobutyrylcysteine Study Group (1999) · European Respiratory Journal · doi:10.1034/j.1399-3003.1999.13d22.x · Cited by 35
E.M. GRANDJEAN, Berthet, P., Ruffmann, R., & LEUENBERGER, P. (2000) · Pharmacological Research · doi:10.1006/phrs.1999.0647 · Cited by 34
Current issues and future directions.
Jf, I. (1984) · PubMed · Cited by 28
Grillage, M. G., & Barnard‐Jones, K. (1985) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.1985.tb07868.x · Cited by 24
Chronic Obstructive Pulmonary Disease
Mitani, A. (2020) · Springer eBooks · doi:10.1007/978-3-030-39903-0_390 · Cited by 11
Cited by
Oxidative stress and redox regulation of lung inflammation in COPD
Rahman, I., & Adcock, I. M. (2006) · European Respiratory Journal · doi:10.1183/09031936.06.00053805 · Cited by 944
N-Acetylcysteine—a safe antidote for cysteine/glutathione deficiency
Atkuri, K. R., Mantovani, J. J., Herzenberg, L. A., & Herzenberg, L. A. (2007) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2007.04.005 · Cited by 721
Rushworth, G. F., & Megson, I. L. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.09.006 · Cited by 719
Mediators of Chronic Obstructive Pulmonary Disease
Barnes, P. J. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.4.2 · Cited by 710
Metadata
- Authors
- Poole, P. J., & Black, P. N.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2001-05-26
- Volume
- 322
- Issue
- 7297
- Pages
- 1271
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- OpenAlex
- W2013697207
- Cited by
- 256
- References
- 27
- FWCI
- 5.86
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.